KaNDy Therapeutics

Description: KaNDy Therapeutics develops NT-814 for menopause symptoms, targeting chronic female hormone-related conditions.

Country: UK

Based in: Stevenage

Founded: 2017

Funding Stage: Series A/B

Tags: ['BioTech', 'MedTech', 'FemTech', 'Menopause', 'Healthcare']

Categories

Add insights to your inbox

We’ll send you content you’ll want to read- and put to use.

Details about how we process your information are available in our Privacy Policy.